Merrion Pharmaceuticals Plc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merrion Pharmaceuticals Plc.
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The Zip surgical skin closure system does not require FDA clearance, but the company is sponsoring a series of trials to demonstrate how it is a faster and less painful approach to healing surgical incisions.